DEFA14A: Avid Bioservices HSR Waiting Period Expires, Acquisition by GHO and Ampersand Nears Completion

Avid Bioservices announces the expiration of the Hart-Scott-Rodino waiting period, bringing its acquisition by GHO Capital Partners and Ampersand Capital Partners closer to completion.

Summary

• Avid Bioservices, a biologics CDMO, announced the expiration of the Hart-Scott-Rodino (HSR) Antitrust Improvements Act waiting period related to its acquisition by GHO Capital Partners and Ampersand Capital Partners.
• The transaction is expected to close in the first quarter of 2025, pending stockholder approval and other customary closing conditions.
• The company has filed a proxy statement with the SEC and mailed the definitive proxy statement and a proxy card to each stockholder entitled to vote at the special meeting to consider the proposed transaction.
• Moelis & Company LLC is serving as exclusive financial advisor to Avid, and Cooley LLP is serving as legal counsel.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the HSR waiting period expiration is a step forward in the acquisition process. However, the deal is still subject to stockholder approval and other conditions, introducing some uncertainty.

Positives

• Expiration of the HSR waiting period removes a regulatory hurdle for the acquisition.
• The transaction is expected to deliver significant, immediate, and certain value to stockholders.
• Management believes the acquisition is in the best interest of all Avid stockholders.

Risks

• The transaction is subject to stockholder approval.
• The transaction is subject to customary closing conditions.
• The transaction could be delayed or terminated due to required governmental and regulatory approvals.
• The transaction could be terminated due to an event, change or other circumstances.
• The transaction could be terminated if the parties are not able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• The transaction could disrupt management time from ongoing business operations.
• The transaction could have adverse effects on the market price of the Company's common stock.
• The transaction could result in unexpected costs or expenses.
• The transaction could result in litigation.
• The transaction could have an adverse effect on the ability of the Company to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally.

Future Outlook

The transaction is expected to close in the first quarter of 2025, subject to Avid stockholder approval and satisfaction of other customary closing conditions.

Management Comments

• Nick Green, president and CEO of Avid Bioservices, stated, 'With this milestone behind us, we are one step closer to completing this transaction and delivering significant, immediate and certain value to our stockholders.'
• Nick Green stated, 'We continue to firmly believe the transaction is in the best interest of all Avid stockholders and we encourage stockholders to vote FOR the transaction today.'

Industry Context

The acquisition reflects ongoing consolidation trends in the CDMO (Contract Development and Manufacturing Organization) industry, driven by the desire to achieve greater scale, expand service offerings, and enhance geographic reach. GHO Capital Partners and Ampersand Capital Partners are private equity firms that invest in healthcare and life sciences companies, so this acquisition is in line with their investment strategies.

Comparison to Industry Standards

• It is difficult to compare this announcement to industry standards as it is a merger announcement and not a financial result.
• However, the CDMO industry is experiencing consolidation, with larger players acquiring smaller ones to expand capabilities and market share.
• Comparable companies that have been involved in similar transactions include Thermo Fisher Scientific's acquisition of PPD and Danaher Corporation's acquisition of Aldevron.

Stakeholder Impact

• Stockholders are expected to receive significant, immediate, and certain value.
• The acquisition could affect the company's ability to retain and hire key personnel.
• The acquisition could affect the company's relationships with customers, vendors, partners, and employees.

Next Steps

• Avid stockholders need to vote on the proposed transaction.
• The parties need to satisfy other customary closing conditions.
• The transaction is expected to close in the first quarter of 2025.

Key Dates

Keywords

Avid Bioservices, acquisition, GHO Capital Partners, Ampersand Capital Partners, CDMO, Hart-Scott-Rodino, HSR, merger, biologics, stockholders